Stephan Ladisch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephan Ladisch has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth L. McClain
Baylor College of Medicine, Houston, Texas, United States
4 shared publications Oussama Abla
Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
3 shared publications- Carlos Rodriguez-Galindo
Department of Global Pediatric Medicine St. Jude Children's Research Hospital Memphis Tennessee USA
2 shared publications - Elena Sieni
15Pediatric Hematology/Oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy
2 shared publications - Jan-Inge Henter
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institute, Stockholm, Sweden
2 shared publications - Maurizio Aricò
Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy
2 shared publications
Latest Publications
- 2 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7429-7449
Central nervous system involvement in children with hemophagocytic lymphohistiocytosis: an HLH-2004 study report
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with an inherited form (primary HLH [pHLH]), of which familial HLH (FHL) is most prevalent, and an acquired (non-Mendelian) form (secondary HLH); both potentially fatal. As more patients survive, evaluating long-term morbidity, especially neurological complications, is important. Here, we report on central nervous system involvement at onset, its impact on mortality and morbidity, and long-term follow-up in 365 children aged <18 years enrolled in the prospective multinational HLH-2004 study. This treatment included etoposide; dexamethasone; cyclosporine; and, for selected patients, intrathecal methotrexate/prednisolone; followed by hematopoietic stem cell transplantation (HSCT) for pHLH. At diagnosis, 33% had neurological symptoms and 57% abnormal cerebral spinal fluid (CSF); 33% and 73%, respectively, in children with verified FHL. Elevated CSF protein was associated with inferior survival in univariate analyses, and multivariate analyses revealed reduced survival in children with both neurological symptoms and abnormal CSF. Overall, 32% of post-HSCT long-term survivors had neurological symptoms at last follow-up, more often in children with abnormal CSF at diagnosis; psychomotor retardation affected 25%, seizures 11%, and attention deficit hyperactivity disorder (ADHD)/autism 10% (at least). Seizures and psychomotor retardation were detected before HSCT in approximately half of children who received HSCT; however, at least 3 years after HSCT in one-third. The median time for reporting ADHD/autism was 5 years after HSCT. Late neurological complications were reported in 7% of long-term survivors without HSCT. In conclusion, late neurological complications remain a major concern in pHLH, CSF evaluation at diagnosis is valuable, and long follow-up is important because complications may be diagnosed late. This trial was registered at www.clinicaltrials.gov as #NCT00426101.
- 2 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7429-7449
Central nervous system involvement in children with hemophagocytic lymphohistiocytosis: an HLH-2004 study report
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with an inherited form (primary HLH [pHLH]), of which familial HLH (FHL) is most prevalent, and an acquired (non-Mendelian) form (secondary HLH); both potentially fatal. As more patients survive, evaluating long-term morbidity, especially neurological complications, is important. Here, we report on central nervous system involvement at onset, its impact on mortality and morbidity, and long-term follow-up in 365 children aged <18 years enrolled in the prospective multinational HLH-2004 study. This treatment included etoposide; dexamethasone; cyclosporine; and, for selected patients, intrathecal methotrexate/prednisolone; followed by hematopoietic stem cell transplantation (HSCT) for pHLH. At diagnosis, 33% had neurological symptoms and 57% abnormal cerebral spinal fluid (CSF); 33% and 73%, respectively, in children with verified FHL. Elevated CSF protein was associated with inferior survival in univariate analyses, and multivariate analyses revealed reduced survival in children with both neurological symptoms and abnormal CSF. Overall, 32% of post-HSCT long-term survivors had neurological symptoms at last follow-up, more often in children with abnormal CSF at diagnosis; psychomotor retardation affected 25%, seizures 11%, and attention deficit hyperactivity disorder (ADHD)/autism 10% (at least). Seizures and psychomotor retardation were detected before HSCT in approximately half of children who received HSCT; however, at least 3 years after HSCT in one-third. The median time for reporting ADHD/autism was 5 years after HSCT. Late neurological complications were reported in 7% of long-term survivors without HSCT. In conclusion, late neurological complications remain a major concern in pHLH, CSF evaluation at diagnosis is valuable, and long follow-up is important because complications may be diagnosed late. This trial was registered at www.clinicaltrials.gov as #NCT00426101.
- Open Access
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4776-4785
Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) confined to the skeleton has excellent survival, yet optimal management of multifocal bone disease and lesions at traditionally defined “special sites” remains uncertain due to limited prospective data. We report prospective results from an international pilot trial embedded within the Histiocyte Society LCH-III study (2001-2008) evaluating 6 months of vinblastine-prednisolone in children with single-system skeletal LCH. Among 455 enrolled patients, 381 were evaluable. Early response at week 6 was achieved in 83% of cases. Five-year overall survival was 100%, and event-free survival (EFS) was 71%. Multifocal bone lesions (MFB) were the dominant predictor of relapse (5-year EFS: 63% vs 87% without MFB; P< .001), whereas isolated central nervous system (CNS)-risk skeletal lesions did not independently affect EFS. In contrast, the cumulative incidence of central diabetes insipidus at 5 years was 5% overall but was significantly higher in patients with CNS-risk lesions, particularly when combined with MFB. These prospective data demonstrate that in single-system skeletal LCH, disease extent and lesion location confer distinct risks, with skeletal multiplicity determining relapse propensity, and anatomic location determining the risk of permanent endocrine sequelae. This study provides a prospective international benchmark for systemic therapy and supports risk-adapted treatment strategies that minimize long-term morbidity while avoiding unnecessary treatment escalation. This trial was registered at www.ClinicalTrials.gov as NCT00276757.
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4776-4785
Open AccessDisease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) confined to the skeleton has excellent survival, yet optimal management of multifocal bone disease and lesions at traditionally defined “special sites” remains uncertain due to limited prospective data. We report prospective results from an international pilot trial embedded within the Histiocyte Society LCH-III study (2001-2008) evaluating 6 months of vinblastine-prednisolone in children with single-system skeletal LCH. Among 455 enrolled patients, 381 were evaluable. Early response at week 6 was achieved in 83% of cases. Five-year overall survival was 100%, and event-free survival (EFS) was 71%. Multifocal bone lesions (MFB) were the dominant predictor of relapse (5-year EFS: 63% vs 87% without MFB; P< .001), whereas isolated central nervous system (CNS)-risk skeletal lesions did not independently affect EFS. In contrast, the cumulative incidence of central diabetes insipidus at 5 years was 5% overall but was significantly higher in patients with CNS-risk lesions, particularly when combined with MFB. These prospective data demonstrate that in single-system skeletal LCH, disease extent and lesion location confer distinct risks, with skeletal multiplicity determining relapse propensity, and anatomic location determining the risk of permanent endocrine sequelae. This study provides a prospective international benchmark for systemic therapy and supports risk-adapted treatment strategies that minimize long-term morbidity while avoiding unnecessary treatment escalation. This trial was registered at www.ClinicalTrials.gov as NCT00276757.
- Open Access
- 12 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5087-5096
Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis
Langerhans cell histiocytosis (LCH) and non-LC histiocytosis are rare neoplastic diseases with variable behavior. Although chemotherapy is effective in many patients, disease recurrence is common, and some patients respond poorly to treatment and/or experience long-term morbidity and mortality. Clofarabine (Clolar), a deoxyadenosine analog, has shown encouraging activity in histiocytic disorders. Here, we report the first prospective, multicenter, phase II study (NCT02425904) evaluating the efficacy and toxicity of clofarabine in recurrent/refractory (R/R) LCH (Stratum 1) and non-LC histiocytosis (Stratum 2). All participants received clofarabine on days 1-5 of each 28-day cycle. Response was assessed after 2 cycles; participants without evidence of disease progression received 4 additional cycles. Twenty-five participants enrolled: 20 in Stratum 1, five in Stratum 2 (including one patient later deemed inevaluable). In Stratum 1, 17/20 participants (85%; 95% CI: [62%, 97%]) were responders, and three had stable disease after cycle 2. Nineteen Stratum 1 participants completed 6 cycles; one withdrew after cycle 3. No Stratum 1 participants progressed during treatment and three had residual or recurrent disease after cycle 6, resulting in 2-year PFS ± SE and OS of 89±7% and 100%, respectively (n=20; median follow-up: 40.9; range: 2.7-49.4). In Stratum 2, 3/4 participants (75%; 95% CI: [19%, 99%]) had partial response. Overall, 80% (20/25) of participants had one or more grade ≥3 toxicities attributed to protocol therapy. In conclusion, clofarabine is active and tolerable in children with R/R LCH and warrants further study in patients with non-LC histiocytosis. Further study of clofarabine in these populations is warranted.
- 12 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5087-5096
Open AccessClofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis
Langerhans cell histiocytosis (LCH) and non-LC histiocytosis are rare neoplastic diseases with variable behavior. Although chemotherapy is effective in many patients, disease recurrence is common, and some patients respond poorly to treatment and/or experience long-term morbidity and mortality. Clofarabine (Clolar), a deoxyadenosine analog, has shown encouraging activity in histiocytic disorders. Here, we report the first prospective, multicenter, phase II study (NCT02425904) evaluating the efficacy and toxicity of clofarabine in recurrent/refractory (R/R) LCH (Stratum 1) and non-LC histiocytosis (Stratum 2). All participants received clofarabine on days 1-5 of each 28-day cycle. Response was assessed after 2 cycles; participants without evidence of disease progression received 4 additional cycles. Twenty-five participants enrolled: 20 in Stratum 1, five in Stratum 2 (including one patient later deemed inevaluable). In Stratum 1, 17/20 participants (85%; 95% CI: [62%, 97%]) were responders, and three had stable disease after cycle 2. Nineteen Stratum 1 participants completed 6 cycles; one withdrew after cycle 3. No Stratum 1 participants progressed during treatment and three had residual or recurrent disease after cycle 6, resulting in 2-year PFS ± SE and OS of 89±7% and 100%, respectively (n=20; median follow-up: 40.9; range: 2.7-49.4). In Stratum 2, 3/4 participants (75%; 95% CI: [19%, 99%]) had partial response. Overall, 80% (20/25) of participants had one or more grade ≥3 toxicities attributed to protocol therapy. In conclusion, clofarabine is active and tolerable in children with R/R LCH and warrants further study in patients with non-LC histiocytosis. Further study of clofarabine in these populations is warranted.
- Open Access
- 15 July 2019
- Published by Wiley in British Journal of Haematology
- Vol. 187 (5) , 559-562
Langerhans cell histiocytosis: progress and controversies
- 15 July 2019
- Published by Wiley in British Journal of Haematology
- Vol. 187 (5) , 559-562
Open AccessLangerhans cell histiocytosis: progress and controversies
- 25 April 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (8) , e27079
Treating Langerhans cell histiocytosis, globally
- 25 April 2018
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (8) , e27079
Treating Langerhans cell histiocytosis, globally
- 1 March 2018
- Published by Elsevier in Cellular Immunology
- Vol. 325, 33-40
IFN-γ and tumor gangliosides: Implications for the tumor microenvironment
- 1 March 2018
- Published by Elsevier in Cellular Immunology
- Vol. 325, 33-40
IFN-γ and tumor gangliosides: Implications for the tumor microenvironment
- Open Access
- 2 July 2015
- Published by American Society of Hematology in Blood
- Vol. 126 (1) , 26-35
How I treat Langerhans cell histiocytosis
“Langerhans cell histiocytosis” (LCH) describes a spectrum of clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease. Regardless of clinical severity, LCH lesions share the common histology of CD1a+/CD207+ dendritic cells with characteristic morphology among an inflammatory infiltrate. Despite historical uncertainty defining LCH as inflammatory vs neoplastic and incomplete understanding of mechanisms of pathogenesis, clinical outcomes have improved markedly over the past decades through cooperative randomized clinical trials based on empiric therapeutic strategies. Significant advances include recognition of high- and low-risk clinical groups defined by hematopoietic and/or hepatic involvement, and of the importance of optimal intensity and of duration of chemotherapy. Nevertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage strategies, and significant disease morbidity of both high- and low-risk patients remain challenges. Recent discovery of recurrent somatic mutations in mitogen-activated protein kinase pathway genes at critical stages of myeloid hematopoietic differentiation in LCH patients supports redefinition of the disease as a myeloproliferative disorder and provides opportunities to develop novel approaches to diagnosis and therapy.
- 2 July 2015
- Published by American Society of Hematology in Blood
- Vol. 126 (1) , 26-35
Open AccessHow I treat Langerhans cell histiocytosis
“Langerhans cell histiocytosis” (LCH) describes a spectrum of clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease. Regardless of clinical severity, LCH lesions share the common histology of CD1a+/CD207+ dendritic cells with characteristic morphology among an inflammatory infiltrate. Despite historical uncertainty defining LCH as inflammatory vs neoplastic and incomplete understanding of mechanisms of pathogenesis, clinical outcomes have improved markedly over the past decades through cooperative randomized clinical trials based on empiric therapeutic strategies. Significant advances include recognition of high- and low-risk clinical groups defined by hematopoietic and/or hepatic involvement, and of the importance of optimal intensity and of duration of chemotherapy. Nevertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage strategies, and significant disease morbidity of both high- and low-risk patients remain challenges. Recent discovery of recurrent somatic mutations in mitogen-activated protein kinase pathway genes at critical stages of myeloid hematopoietic differentiation in LCH patients supports redefinition of the disease as a myeloproliferative disorder and provides opportunities to develop novel approaches to diagnosis and therapy.
- Open Access
- 1 November 2001
- Published by Elsevier in The American Journal of Pathology
- Vol. 159 (5) , 1971-1974
New Approaches to the Molecular Biology, Classification, and Therapy of Nervous System Tumors
- 1 November 2001
- Published by Elsevier in The American Journal of Pathology
- Vol. 159 (5) , 1971-1974
Open AccessNew Approaches to the Molecular Biology, Classification, and Therapy of Nervous System Tumors
- 1 June 1996
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 13 (3) , 385-389
Structural characterization andin vivo immunosuppressive activity of neuroblastoma GD2
Shedding of neuroblastoma gangliosides is positively correlated with tumour progression in patients with neuroblastoma. In assessing the biological activity of these ganglioside molecules, we recently found that total human neuroblastoma gangliosides inhibit cellular immune responses. Here, we have studied the major neuroblastoma ganglioside, GD2. GD2 was purified by high performance liquid chromatography and structurally characterized by mass spectrometry. Immunoregulatory effects of GD2 in vivo were then determined in an established murine model. GD2 significantly downregulated the local cellular immune response to an allogeneic cell challenge; the usual increase in mass of the lymph node draining the injection site was reduced by 88%, from 1.52 to 0.19 mg (control versus GD2-treated mice;p6 cells, and lymphocyte DNA synthesis was reduced to half of the control level. These results show that certain shed tumour gangliosides, such as GD2, function as intercellular signalling molecules, downregulate the cellular immune response, and may thereby enhance tumour formation and progression.
- 1 June 1996
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 13 (3) , 385-389
Structural characterization andin vivo immunosuppressive activity of neuroblastoma GD2
Shedding of neuroblastoma gangliosides is positively correlated with tumour progression in patients with neuroblastoma. In assessing the biological activity of these ganglioside molecules, we recently found that total human neuroblastoma gangliosides inhibit cellular immune responses. Here, we have studied the major neuroblastoma ganglioside, GD2. GD2 was purified by high performance liquid chromatography and structurally characterized by mass spectrometry. Immunoregulatory effects of GD2 in vivo were then determined in an established murine model. GD2 significantly downregulated the local cellular immune response to an allogeneic cell challenge; the usual increase in mass of the lymph node draining the injection site was reduced by 88%, from 1.52 to 0.19 mg (control versus GD2-treated mice;p6 cells, and lymphocyte DNA synthesis was reduced to half of the control level. These results show that certain shed tumour gangliosides, such as GD2, function as intercellular signalling molecules, downregulate the cellular immune response, and may thereby enhance tumour formation and progression.